CORE--PATHOLOGY

病理学核心在组织变化和组织变化的识别方面非常成功 研究三种不同类型的人类结石患者(普通CaOx、肥胖的肠旁路患者合并肾结石和刷石)和GHS大鼠的矿物质沉积位置和晶体类型。在更新中，该核心将监督和执行Lingeman和Evans项目的所有形态分析，使用1)具有特殊染色的光学显微镜，以表征我们新的人类结石成形者组(磷灰石包括RTAS、原发性甲状旁腺功能亢进症、 2)光镜和透射电子显微镜免疫组织化学检测一组已知晶体形成抑制蛋白(骨桥蛋白、凝血酶原片段1、胎球蛋白-A和bikunin)在间质和结石-斑块界面的存在；3)u CT成像以定量、定位和表征整个肾脏或活检标本中新的晶体沉积部位的矿物类型。4)MU FTIR和电子衍射检测技术以确定人活检标本和GHS大鼠肾脏中晶体沉积的特定位置，5)RT-PCR技术以确定普通CaOx结石与肠道旁路或减肥结石的间质中成骨细胞样转录物的存在，6)确定 通过定量颗粒生长/聚集和执行双标记、四线研究来确定CaOx结石成形器中的晶体颗粒形成和结合的机制，7)为Project by COE提供皮质活检样本以用于VDR分析和验证活检位置，以及8)评估GHS大鼠的斑块形成。Lingeman的项目将提供预先确定的人类结石形成组的肾脏(皮质到乳头)的活检样本。威利斯博士将为CoE的Project By Coe进行血清和尿锂分析。

The Pathology Core has been highly successful in the identification of tissue changes and characterizing sites of mineral deposition as well as crystal type in three different type of human stone patients (common CaOx, intestinal bypass patients for obesity with renal stones and brushite) and the GHS rats. In the renewal, this core will oversee and conduct all morphological analyses for Projects by Lingeman and Evans using 1) light micrscopy with special stains to characterize the histopathological patterns and mineral composition of crystal deposition in our new groups of human stone formers (apatite including RTAs, primary hyperparathyroidism, ileostomy, cystinuria, uric acid stones, bariatric and CaOx with high urine pH (> pH 6.3), 2) light and transmission electron microscopic immunohistochemistry to detect the presence of a select group of known inhibitor proteins of crystal formation (osteopontin, prothombin fragment 1, fetuin-A and bikunin) in the interstitium and at the stone-plaque interface, 3) mu CT imaging to quantitate, localize and characterize mineral type of new sites of crystal deposition in whole kidneys or biopsies samples. 4) mu FTIR and electron diffraction detection techniques to identify specific sites of crystal deposition in human biopsy samples and GHS rat kidneys, 5) RT-PCR techniques to determine the presence of osteoblast-like transcripts in the interstitium of the common CaOx stone formers vs intestinal bypass or bariatric stone formers, 6) determine the mechanisms of crystal particle formation and coalescence in CaOx stone formers by quantitating particle growth/coalescence and performing double labeling, tetracyline studies to determine the rate of crystal formation, 7) provide cortical biopsy samples to Project by Coe for VDR analysis and verification of biopsy location, and 8) to assess the GHS rat for plaque formation. Project by Lingeman will supply biopsy samples from the kidney (cortex to papilla) of predetermined groups of human stone formers. Dr. Willis will perform serum and urinary lithium analyses for Project by Coe.